Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9052W HIGH $2.73
Volume
13.34 M
Value Traded
4.93 M
Short % Float
32.08%
-8.13%Week
-6.78%1 Month
-32.23%3 Month
-46.62%6 Month
-85.18%5 Year
-99.8%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
324.02 M
EPS (TTM)
-0.24
P/E Ratio
-
Ent. Value
225.72 M
Total Shares
339.18 M
Float Shares
330.65 M
Insiders
2.49%
Institutions
48.88%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
OCGN Catalyst Timeline
Dated clinical, regulatory and corporate events for Ocugen, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ocugen, Inc.
683Total events
24Upcoming
179Tier-1 (high impact)
2016 to 2029Coverage
Upcoming catalysts 2
Event history 50
●Management ChangeCorporate
Jolanda Crombach appointed General Manager of Ocugen's European affiliate
●R&D DayPresentation
Ocugen executive leadership to present at H.C. Wainwright Biotech on Tap 2026
●Poster PresentationOCU410STPresentation
Clinical Trial Results from GARDian1 Trial - A Novel Modifier Subretinal Gene Therapy for Stargardt Disease at Euretina Congress
Stargardt Diseasesource ↗
●Oral PresentationPresentation
Subretinal RORA-Based Modifier Gene Therapy for GA and Stargardt Disease: Phase 1/2 Safety and Quantitative Lesion Analysis at 26th Euretina Congress
Geographic Atrophy and Stargardt Diseasesource ↗
●Oral PresentationPresentation
Ocugen Company Overview presentation at Euretina Innovation Spotlight (EIS) 2026
▲Other Regulator MilestoneOCU400FiledEx-US Regulatory
OCU400 granted Provisional Approval and Priority Designation by LARTA Board in The Bahamas
retinitis pigmentosasource ↗
▲Tentative ApprovalOCU400FiledFDA Decision
OCU400 granted provisional approval by LARTA Board in The Bahamas
retinitis pigmentosasource ↗
▲Expanded AccessOCU400FiledFDA Decision
OCU400 to be supplied through expanded access program in The Bahamas
retinitis pigmentosasource ↗
▲First Patient DosedOCU410Trial
First patient dosed in Phase 3 ArMaDa3 trial
geographic atrophy secondary to dry age-related macular degenerationsource ↗
▲Full ResultsOCU410Clinical Data
12-month Phase 2 data reported
geographic atrophy secondary to dry age-related macular degenerationsource ↗
▲IND ClearanceOCU410IND
FDA clearance to initiate OCU410 Phase 3 trial for GA
geographic atrophy secondary to dry age-related macular degenerationsource ↗
▲RMATOCU410Designation
RMAT designation granted for OCU410
geographic atrophy secondary to dry age-related macular degenerationsource ↗
▲Enrollment CompleteOCU410STTrial
Completed enrollment and dosing of 63 subjects in GARDian3 trial
Stargardt diseasesource ↗
▲Enrollment CompleteOCU400FiledTrial
Completed enrollment in liMeliGhT trial (N=140)
retinitis pigmentosasource ↗
▲Manufacturing MilestoneOCU400FiledCMC / Inspection
Completed OCU400 Process Performance Qualification (PPQ) batches
retinitis pigmentosasource ↗
▲Partnership / LicenseOCU400FiledCorporate
Signed binding term sheet with Roots Pharmaceutical for exclusive OCU400 license in MENA
retinitis pigmentosasource ↗
●FDA Feedback ReceivedOCU400FiledFDA Meeting
FDA feedback on rolling BLA submission path
retinitis pigmentosasource ↗
◆Oral PresentationPresentation
Ocugen to present at Oppenheimer 4th Annual Biotech in the Berkshires Summit
▲RMATOCU410Designation
FDA granted RMAT designation
geographic atrophy secondary to dry age-related macular degenerationsource ↗
▲Partnership / LicenseOCU400FiledCorporate
Binding term sheet signed with Roots Pharmaceutical for OCU400 in MENA region
Retinitis Pigmentosasource ↗
●Trial InitiationOCU410Trial
OCU410 Phase 3 trial initiation expected this quarter
geographic atrophy secondary to dry age-related macular degenerationsource ↗
▲End Of Phase 2 MeetingOCU410FDA Meeting
Type B End-of-Phase 2 meeting with FDA
geographic atrophy secondary to dry age-related macular degenerationsource ↗
▲FDA Feedback ReceivedOCU410FDA Meeting
FDA alignment on Phase 3 registrational trial design
geographic atrophy secondary to dry age-related macular degenerationsource ↗
◆Oral PresentationPresentation
Clinical Trials at the Summit 2026 - Inherited Retinal Diseases Panel
◆Oral PresentationPresentation
Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference
◆Timing GuidanceOCU400FiledPresentation
Potential BLA and MAA filings for OCU400 by mid-2026
retinitis pigmentosasource ↗
▼Equity OfferingCorporate
Closing of $130.0 million 6.75% Convertible Senior Notes due 2034, including full exercise of $15.0 million over-allotment option
▼Equity OfferingCorporate
Closing of $115M private offering of 6.75% convertible senior notes due 2034
▲Enrollment CompleteOCU400FiledTrial
Completed Phase 3 liMeliGhT enrollment for OCU400 (N=140)
retinitis pigmentosasource ↗
▲Enrollment CompleteOCU410STTrial
Completed enrollment and dosing for OCU410ST Phase 2/3 GARDian3 trial (N=63)
Stargardt diseasesource ↗
▲Enrollment CompleteOCU400FiledTrial
Completed enrollment in Phase 3 liMeliGhT trial
Retinitis Pigmentosasource ↗
▲Full ResultsOCU400FiledClinical Data
Positive long-term 3-year Phase 1/2 data assessed
Retinitis Pigmentosasource ↗
▲Trial CompletionOCU410Trial
Completed dosing in Phase 2 of Phase 1/2 ArMaDa trial
Geographic atrophy (advanced dAMD)source ↗
◆Oral PresentationPresentation
Oppenheimer Innovation on the Island Biotech Summit presentation
▲Enrollment CompleteOCU410STTrial
Enrollment and dosing completed in Phase 2/3 GARDian3 trial (N=63)
Stargardt diseasesource ↗
●Manufacturing MilestoneOCU400FiledCMC / Inspection
Completion of PPQ batches for OCU400 manufacturing
retinitis pigmentosasource ↗
◆Interim AnalysisOCU410STTrial
OCU410ST interim data on 50% of patients at eight months of treatment expected mid-year 2026
Stargardt diseasesource ↗
◆Timing GuidanceOCU400FiledPresentation
Potential BLA/MAA filings for OCU400 by mid-2026
retinitis pigmentosasource ↗
Past FDA Catalysts and PDUFA Decisions
How OCGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-09 | OCU410ST | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C46 / 100
Pipeline Score
$10M
Pipeline Value
Richly Valued
Valuation Signal
5
Drugs Scored
0.0x
rNPV / MCap
Top 26%
Micro Cap(rank 172 of 660)
Percentile Rank
Ocugen, Inc. carries a moderate pipeline score (46/100), with $48M risk-adjusted pipeline value, led by OCU200 in Center Involved Diabetic Macular Edema (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OCU200 Small moleculeNCT05802329 | Center Involved Diabetic Macular Edema | Phase 1 | RECRUITING | 24 | Jul 31, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every OCGN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| OCU410 RMATOrphanRare Pediatric | geographic atrophy secondary to dry age-related macular degeneration | Phase 3 | 2026-09-01 | 31% reduction in lesion growthRead More | Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Musunuri ShankarDirector, Officer (Chief Executive Officer) | Sell | -468,727 4,487,197 held | $1.12 | 09/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in OCGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0.1 % | 10.20 M | 6.67 M |
OCGN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How OCGN ranks across every disease it competes in
Competitive Position is a premium feature
See how OCGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialOCGN News
OCGNOcugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
Ocugen has appointed Jolanda Crombach as General Manager of its European affiliate in Amsterdam. This move aims to bolster the company's presence in Europe as it advances its three Phase 3 gene therapy programs for blindness diseases. Crombach's extensive experience in the pharmaceutical industry is expected to support upcoming marketing authorization submissions and potential commercialization efforts.
Read more →OCGN▼ -5.5%on this news
Ocugen to Participate in Upcoming Scientific Conferences
Ocugen, Inc. announced its participation in several upcoming scientific conferences, where it will present on its innovative modifier gene therapy platform. Key presentations include safety and efficacy results from its Phase 2 ArMaDa Trial and other studies related to gene therapies for blindness diseases. The conferences will take place in Vienna and New Orleans in October 2026.
Read more →OCGN▲ +5.8%on this newsshared move
Ocugen to Participate in Upcoming October Investor and Industry Conferences
Ocugen, Inc. will present at two upcoming investor and industry conferences in October 2026. The first event is the H.C. Wainwright: Biotech on Tap 2026 in Munich, followed by the Cell & Gene Meeting on the Mesa 2026 in Phoenix. CEO Dr. Shankar Musunuri will lead discussions on financing solutions and the future of cell and gene therapy.
Read more →OCGNOcugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
Ocugen has received provisional approval and priority designation for its investigational gene therapy OCU400 from the Longevity and Regenerative Therapies Board in The Bahamas. The company plans to provide OCU400 through an expanded access program, aiming to treat the first patient with retinitis pigmentosa within 90 days. OCU400 is currently in Phase 3 trials, with topline data expected in early 2027 and a Biologics License Application submission planned for mid-2027.
Read more →OCGNOcugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Ocugen has initiated dosing in a global Phase 3 trial for OCU410, a gene therapy targeting geographic atrophy secondary to dry age-related macular degeneration. The FDA has granted OCU410 Regenerative Medicine Advanced Therapy designation, which may lead to accelerated approval. The trial aims to evaluate the therapy's efficacy and safety in a multicenter study involving 237 subjects.
Read more →OCGNOcugen to Participate in Upcoming September Investor and Industry Conferences
Ocugen, Inc. will present its gene therapy platform at several conferences in September 2026. CEO Dr. Shankar Musunuri will lead discussions at the Citi Biopharma Conference and H.C. Wainwright Investment Conference. Additionally, Dr. Raj K. Maturi will present results from a Phase 2 trial of OCU410 gene therapy at The Retina Society's annual meeting.
Read more →OCGNOcugen Provides Business Update with Second Quarter 2026 Financial Results
Ocugen reported a strong second quarter in 2026, highlighting FDA clearance for the Phase 3 trial of OCU410 for geographic atrophy and the successful completion of OCU400's Process Performance Qualification. The company secured $130 million in financing, extending its cash runway into 2028. Additionally, Ocugen signed a term sheet for an exclusive license of OCU400 in the MENA region and appointed new leadership members.
Read more →OCGNOcugen to Participate in Upcoming August Investor Conferences
Ocugen, Inc. will present its innovative modifier gene therapy platform at two upcoming investor conferences in August 2026. The first event is the Oppenheimer 4th Annual Biotech in the Berkshires Summit on August 4, followed by the Canaccord 46th Annual Growth Conference on August 11. These presentations aim to highlight the company's advancements in gene therapies for blindness diseases.
Read more →OCGNOcugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
Ocugen has announced that the FDA granted RMAT designation to its investigational therapy OCU410 for treating geographic atrophy secondary to dry age-related macular degeneration. This designation aims to expedite the development process due to the significant unmet medical need in this area. Phase 2 clinical data demonstrated promising efficacy and safety, paving the way for a Phase 3 trial expected to begin in Q3 2026.
Read more →OCGNOcugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
Ocugen, Inc. will host a conference call on August 6, 2026, at 8:30 a.m. ET to discuss its second quarter financial results and provide business updates. The call will be accessible via dial-in and webcast, with a replay available afterward. The company focuses on gene therapies for blindness diseases, aiming to meet substantial medical needs.
Read more →OCGNOcugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Ocugen, Inc. has announced a binding term sheet with Roots Pharmaceutical to negotiate a license agreement for OCU400, a gene therapy for Retinitis Pigmentosa, in the MENA region. The agreement includes potential sales milestones of up to $255 million and a 22% royalty on net sales. Ocugen will also manufacture OCU400, addressing a significant unmet need in the region. The definitive agreement is expected within 90 days, with ongoing clinical trials for OCU400.
Read more →OCGNOcugen to Participate in Upcoming July Industry Conferences
Ocugen, Inc. will participate in several industry conferences in July 2026, showcasing its modifier gene therapy platform aimed at treating blindness diseases. Key events include a fireside chat at Piper Sandler's Virtual Ophthalmology Day and presentations at the OIS Retina Innovation Summit and ASRS meeting. These engagements highlight Ocugen's commitment to addressing significant unmet medical needs in ophthalmology.
Read more →OCGNOcugen to Participate in Upcoming June Investor and Industry Conferences
Ocugen, Inc. announced its participation in several upcoming investor and industry conferences in June 2026. The company will present its innovative modifier gene therapy platform, which aims to address inherited retinal diseases. Key events include the Noble Capital Markets Emerging Growth Virtual Equity Conference and the BIO International Convention. A webcast of the presentations will be available on their website.
Read more →OCGNOcugen, Inc. Announces Closing for $130.0 Million
Ocugen, Inc. has announced the successful closing of $130 million in 6.75% Convertible Senior Notes, including a full exercise of an over-allotment option. The financing is expected to provide around $112.6 million in net proceeds, which Ocugen will use to repay its existing loan and support general corporate purposes. The company aims to advance its late-stage gene therapies for treating blindness diseases and targets filing three Biologics License Applications (BLAs) by 2028. However, there are inherent risks associated with the offering and potential dilution effects on existing shareholders.
Read more →OCGNOcugen to Participate in Upcoming May Scientific and Investor Conferences
Ocugen, Inc. will showcase its innovative modifier gene therapy platform at two upcoming conferences in May 2026. The Retina World Congress will feature a session on inherited and rare retinal diseases, while the Stifel 2026 Virtual Ophthalmology Forum will also highlight the company's advancements. These presentations aim to address significant medical needs in treating blindness diseases.
Read more →OCGN▼ -19.5%on this news
Ocugen Provides Business Update with First Quarter 2026 Financial Results
Ocugen reported positive results from its OCU410 Phase 2 trial, showing a significant reduction in lesion size for geographic atrophy. The company completed enrollment for two late-stage trials and plans to submit Biologics License Applications by 2027. A recent $115 million offering is expected to extend its cash runway into 2028, supporting ongoing clinical programs.
Read more →OCGN▼ -19.5%on this newsshared move
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
Ocugen, Inc. has announced the pricing of $115 million in 6.75% Convertible Senior Notes due in 2034. The offering is aimed at qualified institutional buyers and is expected to yield approximately $99.5 million in net proceeds. Funds will be utilized primarily to repay existing debt and for general corporate purposes. The notes will mature in 2034 and have specific terms regarding conversion and redemption.
Read more →OCGNExcerpts from Preliminary Offering Memorandum Overview We are a biotechnology company focused on discovering, developing, and commercializing novel gene therapies that improve health and offer hope for patients across th
Ocugen, Inc. (OCGN) has published an overview of its biotechnology offerings, particularly focusing on its gene therapy pipelines. The company is making strides with OCU400, which has received favorable opinions from the EMA and is currently enrolled in Phase 3 trials. They anticipate a rolling Biologics License Application (BLA) submission for OCU400 in Q3 2026, with Phase 3 data expected in Q1 2027. Additionally, they are advancing OCU410ST into pivotal trials and aim to submit several BLAs by 2028.
Read more →OCGNOcugen Announces Private Offering of $115 Million of Convertible Senior Notes
Ocugen, Inc. has announced a private offering of $115 million in Convertible Senior Notes due 2034. The proceeds will primarily be used to repay existing debts and for general corporate purposes. The offering is contingent on market conditions, and there are risks associated with its completion and potential dilution for current shareholders.
Read more →OCGNOcugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
Ocugen, Inc. will host a conference call on May 5, 2026, at 8:30 a.m. ET to discuss its first quarter financial results and provide business updates. The call will include a pre-market earnings announcement and will be accessible via dial-in and webcast. A replay will be available afterward.
Read more →About Ocugen, Inc.
Headquarters11 GREAT VALLEY PARKWAY, MALVERN, PA, 19355
BIOPHARMAWATCH ELITE PLUS
Trade the next OCGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime